Cargando…
Characterization of SET/I2PP2A Isoforms in Dogs
SET is an endogenous protein phosphatase 2A (PP2A) inhibitor and is associated with a poor prognosis in human leukemia. Previously, we reported increased SET protein levels in canine lymphoma cell lines and the potential therapeutic application of SET antagonists in canine lymphoma. Here, we found t...
Autores principales: | YABE, Ryotaro, FUJIWARA, Nobuyuki, MIZUNO, Takuya, USUI, Tatsuya, OHAMA, Takashi, SATO, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Veterinary Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197151/ https://www.ncbi.nlm.nih.gov/pubmed/24897959 http://dx.doi.org/10.1292/jvms.14-0209 |
Ejemplares similares
-
The therapeutic effects of SET/I2PP2A inhibitors on canine
melanoma
por: ENJOJI, Shuhei, et al.
Publicado: (2015) -
Anti-tumor effects of perphenazine on canine lymphoma
por: TSUJI, Shunya, et al.
Publicado: (2016) -
A stable association with PME‐1 may be dispensable for PP2A demethylation – implications for the detection of PP2A methylation and immunoprecipitation
por: Yabe, Ryotaro, et al.
Publicado: (2018) -
The role of SET/I2PP2A in canine mammary tumors
por: Kake, Satoru, et al.
Publicado: (2017) -
Protein Phosphatase Methyl-Esterase PME-1 Protects Protein Phosphatase 2A from Ubiquitin/Proteasome Degradation
por: Yabe, Ryotaro, et al.
Publicado: (2015)